|
Market Closed -
NSE India S.E.
11:05:08 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2,300.00 INR | +1.51% |
|
+4.06% | +13.01% |
| 09-11 | Glenmark Pharmaceuticals Limited Proposes Dividend for the Year Ended 31 March 2026 | CI |
| 09-07 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
Company Valuation: Glenmark Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 124,718 | 131,124 | 270,463 | 434,866 | 601,567 | 649,062 | - | - |
| Change | - | 5.14% | 106.27% | 60.79% | 38.33% | 7.9% | - | - |
| Enterprise Value (EV) 1 | 150,223 | 162,699 | 263,786 | 442,540 | 595,740 | 613,312 | 601,900 | 591,938 |
| Change | - | 8.3% | 62.13% | 67.76% | 34.62% | 2.95% | -1.86% | -1.66% |
| P/E | 13.2x | 44.1x | -18x | 41.5x | 44.2x | 28.1x | 23.2x | 20.8x |
| PBR | 1.37x | 1.38x | 3.45x | 4.91x | 5.72x | 5.18x | 4.28x | 3.67x |
| PEG | - | -0.6x | 0x | -0x | 1.5x | 0.4x | 1.1x | 1.8x |
| Capitalization / Revenue | 1.01x | 1.01x | 2.29x | 3.26x | 3.54x | 3.83x | 3.47x | 3.09x |
| EV / Revenue | 1.22x | 1.25x | 2.23x | 3.32x | 3.51x | 3.62x | 3.21x | 2.81x |
| EV / EBITDA | 6.47x | 7.14x | 22.1x | 18.8x | 13x | 16.9x | 13.8x | 12.2x |
| EV / EBIT | 8.19x | 9.76x | 43x | 23.7x | 14.9x | 20x | 16.3x | 14.9x |
| EV / FCF | 47.2x | 923x | -22.7x | -28.1x | 28.5x | 36.9x | 31.8x | 27.4x |
| FCF Yield | 2.12% | 0.11% | -4.41% | -3.56% | 3.5% | 2.71% | 3.15% | 3.65% |
| Dividend per Share 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3.82 | 4.02 | 3.75 |
| Rate of return | 0.57% | 0.54% | 0.26% | 0.16% | 0.12% | 0.17% | 0.17% | 0.16% |
| EPS 2 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 81.95 | 99.11 | 110.6 |
| Distribution rate | 7.49% | 23.7% | -4.7% | 6.74% | 5.18% | 4.66% | 4.06% | 3.39% |
| Net sales 1 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 169,493 | 187,310 | 210,339 |
| EBITDA 1 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,398 | 43,540 | 48,545 |
| EBIT 1 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 30,630 | 36,990 | 39,859 |
| Net income 1 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 23,694 | 28,322 | 30,213 |
| Net Debt 1 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -35,750 | -47,162 | -57,124 |
| Reference price 2 | 442.00 | 464.70 | 958.45 | 1,541.05 | 2,131.70 | 2,300.00 | 2,300.00 | 2,300.00 |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | 282,201 | - | - |
| Announcement Date | 27/05/22 | 19/05/23 | 24/05/24 | 23/05/25 | 29/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.65x | 3.56x | 16.58x | 0.17% | 6.73B | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 29.39x | 6.73x | 18.55x | 1.92% | 403.43B | |
| Weighted average by Cap. | 35.26x | 8.35x | 20.47x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLENMARK Stock
- Valuation Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
